Homburger advised Kuros Biosurgery Holding in the business combination with Cytos Biotechnology into SIX-listed Kuros Biosciences

On January 20, 2015, Kuros Biosciences AG (SIX: KURN, formerly CYTN) announced the completion of the combination of Cytos Biotechnology AG (Cytos) and Kuros Biosurgery Holding AG (Kuros). The transaction was structured as a reverse merger in which Kuros’ shareholders exchanged their Kuros shares for new Cytos shares. As a result, the former Kuros shareholders hold almost four-fifths of the outstanding share capital of Cytos, which was renamed “Kuros Biosciences AG” and whose shares continue to be listed on the SIX Swiss Exchange.

Kuros Biosciences AG is a company focusing primarily on the development of products for tissue repair and regeneration based in Schlieren (Zurich), Switzerland. The board of directors and executive management of Kuros Biosciences AG consists of representatives of both Kuros and Cytos.

Kuros was advised by Homburger in this transaction. The Homburger team was led by partner Dieter Gericke (Corporate / M&A) and included partner Reto Heuberger (Tax), associates Sergio Bortolani and Daniel Häusermann (both Corporate / M&A) and Pascal Meier (Litigation / Arbitration) as well as junior associate Nicolas Jauslin (Corporate / M&A).